SGI‐110/NCT01696032.

Trial name or title	A randomised, controlled, open‐label, phase 2 trial of SGI‐110 and carboplatin in subjects with platinum‐resistant recurrent ovarian cancer
Methods	Phase II open‐label RCT
Participants	116 women with PR ROC
Interventions	SGI‐110 + carbo versus PLD (40 mg/m²) or TOP or paclitaxel
Outcomes	Primary; SAE, PFS, CA125 Secondary: ORR, duration of response, OS
Starting date	Oct 2012
Contact information	Astex Pharmaceuticals; Medpace Recruitment Center
Notes	End Date: Jul 2014